| Authors: |
Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston joyce_liu@dfci.harvard.edu., Moore KN; Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City., Birrer MJ; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston., Berlin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.; Department of Oncology, New England Cancer Care Specialists, Kennebunk., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville., Wolpin B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston., Poon KA; Early Development, Genentech, South San Francisco, USA., Firestein R; Early Development, Genentech, South San Francisco, USA., Xu J; Early Development, Genentech, South San Francisco, USA., Kahn R; Early Development, Genentech, South San Francisco, USA., Wang Y; Early Development, Genentech, South San Francisco, USA., Wood K; Early Development, Genentech, South San Francisco, USA., Darbonne WC; Early Development, Genentech, South San Francisco, USA., Lackner MR; Early Development, Genentech, South San Francisco, USA., Kelley SK; Early Development, Genentech, South San Francisco, USA., Lu X; Early Development, Genentech, South San Francisco, USA., Choi YJ; Early Development, Genentech, South San Francisco, USA., Maslyar D; Early Development, Genentech, South San Francisco, USA., Humke EW; Early Development, Genentech, South San Francisco, USA., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville. |
